STL Index for: Risankizumab
Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.
This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.
The addition of biologics that target IL-23p19 (Risankizumab) to our therapeutic armamentarium has succeeded in improving outcomes in patients with moderate-to-severe plaque psoriasis.
Latest drug update covers Pembrolizumab for IV injection (Keytruda®, Merck & Co.), Guselkumab for SC injection (Tremfya®, MorphoSys/Janssen), Dupilumub for SC injection (Dupixent®, Regeneron), and Risankizumab for SC injection (Skyrizi™, AbbVie).